News | November 15, 2022
Orchid Pharma reports positive EBIDTA in Q2
The company is focussed on increasing the capacity utilizations while controlling costs
The company is focussed on increasing the capacity utilizations while controlling costs
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
CGHS would give robust coverage to pensioners and with new innovations and practices
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
Subscribe To Our Newsletter & Stay Updated
